Oncology Clinical Trials

  1. TH1902 is in early phase development in cancer patients with advanced solid tumors. The FDA has granted a Fast-Track development program for the investigation of TH1902 as a single agent, for the treatment of patients with sortilin positive recurrent advanced solid tumors that are refractory to standard therapy.
  2. TH1902-CTR-0001 (ClinicalTrials.gov Identifier: NCT04706962) is an open label first in human (FIH) study of TH1902 in solid cancers. Patient recruitment has recently been voluntarily paused. The Company is currently analyzing the data obtained thus far from this trial and plans on filing an amended protocol with the FDA, subject to their approval, prior to pursuing the trial.